Target intelligence / Profile preview

DOTA-chelated lanthanide metal complex

Molecular classification
Other (synthetic chelate complex), Paramagnetic contrast agent (when containing Gd), Radiometal chelator (with Lu-177, Y-90, etc.)
01

Overview

DOTA-chelated lanthanide metal complexes are synthetic molecules where the macrocyclic ligand DOTA securely binds a trivalent lanthanide metal ion (such as gadolinium, lutetium, or yttrium). These highly stable chelates are widely employed as contrast agents in magnetic resonance imaging (MRI), as radiopharmaceuticals for targeted cancer imaging and therapy, and in experimental biosensing applications. The DOTA framework endows exceptional thermodynamic and kinetic stability to the complex, reducing metal ion release and associated toxicity risks. When conjugated to tumor-targeting moieties, DOTA-lanthanide complexes enable highly specific visualization or therapeutic delivery to disease sites. These are not conventional biomolecular targets, but engineered molecular entities designed for clinical diagnostics, therapy, and increasingly, advanced research applications.

Other names
DOTA-lanthanide complexLanthanide-DOTA chelateGd-DOTADOTMA-chelated lanthanides
02

Mechanism of action

DOTA chelates stabilize the lanthanide ion, enabling its use in imaging (paramagnetic for MRI, radioactive for PET/SPECT), and in targeted radiotherapy by directing cytotoxic radiation to specific tissues

03

Biological functions

Contrast enhancement in magnetic resonance imaging (MRI)Radiopharmaceutical for imaging (PET/SPECT) or therapyBiosensing and cell tracking in experimental settings
04

Disease associations

Cancer diagnostic imaging and targeted radiotherapyNeurodegenerative disease (MRI imaging of brain)Cardiovascular disease imaging
05

Safety considerations

Risk of release of toxic free lanthanide ions if chelation is incomplete (e.g., Gd toxicity in nephrogenic systemic fibrosis)Radiotoxicity (when carrying radioactive metals such as Lu-177 or Y-90)Allergic reactions, rare but possible (more likely due to carrier molecules than DOTA-metal itself)
06

Interacting drugs

Gadoterate meglumine (Gd-DOTA)

2 more in the full profile.

07

Biomarkers

Tumor-specific antigens (when DOTA-metal is conjugated to targeting ligands like monoclonal antibodies)No intrinsic biomarker function; used as imaging agents when attached to targeting molecules

Beyond the preview

Go deeper on DOTA-chelated lanthanide metal complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DOTA-chelated lanthanide metal complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call